In wake of cancer drug rejection, Aveo Oncology plots a comeback

The first surprise upon entering the offices of Aveo Oncology for an interview a month ago was simply how busy the labs are at the biotech known mostly for one of the most high-profile drug rejections of 2013...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.